OnabotulinumtoxinA ( DrugBank: OnabotulinumtoxinA )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	1
149	Hemiconvulsion hemiplegia epilepsy syndrome	1
226	Interstitial cystitis with Hunners ulcer	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03069911 (ClinicalTrials.gov)	November 1, 2018	28/2/2017	Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease	Parkinson Disease;Depression	Biological: OnabotulinumtoxinA;Biological: Control	Johns Hopkins University	NULL	Terminated	18 Years	95 Years	All	3	Phase 1	United States

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01600716 (ClinicalTrials.gov)	June 13, 2012	15/5/2012	Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)		Urinary Incontinence;Multiple Sclerosis;Neurogenic Bladder	Biological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline)	Allergan	NULL	Completed	18 Years	N/A	All	144	Phase 3	United States;Belgium;Canada;Czechia;France;Poland;Portugal;Russian Federation;Czech Republic

Clinical trials : 25 / Drugs : 35 - (DrugBank : 13) / Drug target genes : 16 - Drug target pathways : 22

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05615987 (ClinicalTrials.gov)	December 1, 2022	2/11/2022	Comparison of Botulinum Toxin Injection Techniques in Spasticity	Comparison of the Efficacy of 2 Different Botulinum Toxin Injection Techniques in Gastrocnemius Muscle Spasticity in Hemiplegic Patients: A Randomized Double-blind Controlled Study.	Spastic Hemiplegia	Drug: Onabotulinumtoxina for Injection	Konya Beyhekim Training and Research Hospital	NULL	Not yet recruiting	18 Years	90 Years	All	60	Phase 4	Turkey

Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03076762 (ClinicalTrials.gov)	March 2015	1/3/2017	Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis	Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial	Bladder Pain Syndrome	Drug: intravesical onabotulinumtoxinA injection	Buddhist Tzu Chi General Hospital	NULL	Recruiting	18 Years	N/A	All	60	Phase 2	Taiwan